Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study
TL;DR: The older and S3 stage of fibrosis may be risk factors for progression to cirrhosis in CHB patients with HS, and HS may aggravate liver disease, promoting HCC progression.
Journal ArticleDOI
The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients
TL;DR: The HCC incidence in patients treated with entecvir was similar to that of those treated with lamivudine, although entecavir exhibits a stronger viral suppression than lamivUDine, and the loss of the hepatitis B surface antigen (HBsAg) by interferon or NA was correlated with a lower HCC occurrence rate.
Journal ArticleDOI
Common variants of the TLR9 gene influence the clinical course of HBV infection
TL;DR: This study is the first to show that small effects within TLR9 contribute towards the development of HBV, supporting the hypothesis that little is currently known regarding the contribution of genetic factors to HBV.
Journal ArticleDOI
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
L. Stella,Francesco Santopaolo,Antonio Gasbarrini,Maurizio Pompili,Francesca Romana Ponziani +4 more
TL;DR: Viral and microenvironmental factors contributing to HCC occurrence in patients with chronic viral hepatitis are outlined and the importance of surveillance programs recommended by international guidelines to promote early diagnosis of HCC is pointed out.
Journal ArticleDOI
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history
TL;DR: PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.